These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 28151013

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas.
    Bao Z, Ji W, Yang Y, Chen Z, Li Z, Wang K, Lu T, Yu Y, Xia W, Lu S.
    Exp Cell Res; 2020 Oct 15; 395(2):112187. PubMed ID: 32721391
    [Abstract] [Full Text] [Related]

  • 29. Gli1 expression in cancer stem-like cells predicts poor prognosis in patients with lung squamous cell carcinoma.
    Cui Y, Cui CA, Yang ZT, Ni WD, Jin Y, Xuan YH.
    Exp Mol Pathol; 2017 Apr 15; 102(2):347-353. PubMed ID: 28286162
    [Abstract] [Full Text] [Related]

  • 30. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC.
    Xia Y, Wu Y, Liu B, Wang P, Chen Y.
    FEBS Lett; 2014 Jun 27; 588(14):2238-45. PubMed ID: 24842609
    [Abstract] [Full Text] [Related]

  • 31. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells.
    Hu C, Liu D, Zhang Y, Lou G, Huang G, Chen B, Shen X, Gao M, Gong W, Zhou P, Dai S, Zeng Y, He F.
    Oncogene; 2014 May 29; 33(22):2888-97. PubMed ID: 23812424
    [Abstract] [Full Text] [Related]

  • 32. Sox2 promotes tumor aggressiveness and epithelial‑mesenchymal transition in tongue squamous cell carcinoma.
    Liu X, Qiao B, Zhao T, Hu F, Lam AK, Tao Q.
    Int J Mol Med; 2018 Sep 29; 42(3):1418-1426. PubMed ID: 29956740
    [Abstract] [Full Text] [Related]

  • 33. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
    Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Ribeiro U, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.
    Nat Genet; 2009 Nov 29; 41(11):1238-42. PubMed ID: 19801978
    [Abstract] [Full Text] [Related]

  • 34. Homeobox Transcription Factor NKX2-1 Promotes Cyclin D1 Transcription in Lung Adenocarcinomas.
    Harada M, Sakai S, Ohhata T, Kitagawa K, Mikamo M, Nishimoto K, Uchida C, Niida H, Kotake Y, Sugimura H, Suda T, Kitagawa M.
    Mol Cancer Res; 2017 Oct 29; 15(10):1388-1397. PubMed ID: 28634225
    [Abstract] [Full Text] [Related]

  • 35. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer.
    Mukhopadhyay A, Berrett KC, Kc U, Clair PM, Pop SM, Carr SR, Witt BL, Oliver TG.
    Cell Rep; 2014 Jul 10; 8(1):40-9. PubMed ID: 24953650
    [Abstract] [Full Text] [Related]

  • 36. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA.
    Clin Cancer Res; 2004 Nov 15; 10(22):7764-74. PubMed ID: 15570011
    [Abstract] [Full Text] [Related]

  • 37. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
    Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB.
    Cancer Res; 2002 Jun 15; 62(12):3351-5. PubMed ID: 12067972
    [Abstract] [Full Text] [Related]

  • 38. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model.
    Sauter ER, Herlyn M, Liu SC, Litwin S, Ridge JA.
    Clin Cancer Res; 2000 Feb 15; 6(2):654-60. PubMed ID: 10690551
    [Abstract] [Full Text] [Related]

  • 39. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.
    Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, Brohée S, Salmon I, Dubois C, del Marmol V, Fuks F, Beck B, Blanpain C.
    Nature; 2014 Jul 10; 511(7508):246-50. PubMed ID: 24909994
    [Abstract] [Full Text] [Related]

  • 40. Jmjd2c maintains the ALDHbri+ cancer stemness with transcription factor SOX2 in lung squamous cell carcinoma.
    Wang M, Hu Y, Cai F, Guo L, Mao Y, Zhang Y.
    Cancer Biol Ther; 2024 Dec 31; 25(1):2373447. PubMed ID: 38975736
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.